Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.39 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.39 |
| ▸ | HEXD | Q8WVB3 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748187 | 0.87 | P2RX7 (0.46) | P2RX7SETDB1HEXDROCK2ROCK1 | |
| SCHEMBL2749953 | 0.87 | ROCK2 (0.45) | CNR1ROCK2ROCK1ALDH1A1LMNA | |
| SCHEMBL2749081 | 0.84 | ALDH1A1 (0.42) | MMP2P2RX7SETDB1KDM4EALDH1A1 | |
| SCHEMBL2748481 | 0.84 | LMNA (0.52) | ERCC1ERCC4P2RX7ALDH1A1LMNA | |
| SCHEMBL2748200 | 0.83 | PTGES (0.41) | ERCC1ERCC4MMP2ALDH1A1LMNA | |
| SCHEMBL19643240 | 0.82 | MEN1 (0.41) | MMP2DDR1HEXDKDM4EALDH1A1 | |
| SCHEMBL2749414 | 0.79 | ALDH1A1 (0.43) | P2RX7SLC1A2ALDH1A1LMNA | |
| SCHEMBL18769973 | 0.79 | TSHR (0.52) | HEXDALDH1A1 | |
| SCHEMBL29567928 | 0.79 | TSHR (0.52) | HEXDALDH1A1 | |
| SCHEMBL18791331 | 0.78 | CARM1 (0.49) | ERCC1ERCC4ROCK2ROCK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | ERCC1 4215/4885ERCC4 4816/4885MMP2 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.